Background/Aims: Myocardial ischemia/reperfusion (I/R) injury (MI/RI) is a critical cause of death in patients with heart disease. However, the pharmaco-therapeutical outcome for MI/RI remains unsatisfactory. Innovative approaches for enhancing drug sensitivity and recovering myocardial function in MI/RI treatment are urgently needed. The purpose of this study was to evaluate the protective effects of exenatide-loaded poly(L-lysine)-poly(ethylene glycol)-poly(L-lysine) (PLL-PEG-PLL) nanoparticles (NPs) against MI/RI. Methods: The size of PLL-PEG-PLL NPs and the loading and release rates of exenatide were determined. The in vitro NP cytotoxicity was evaluated using newborn rat cardiomyocytes. Rats pretreated with free exenatide or exenatide/PLL-PEG-PLL polyplexes were subjected to 0.5-h ischemia and 2-h reperfusion in the left anterior descending coronary artery. The histopathologic lesions were assessed using hematoxylin-eosin staining. The general physiological indices, including blood pressure (BP), heart rate (HR), the left ventricular ejection fraction (LVEF) and end-diastolic pressure (LEVDP), and the left ventricular pressure maximal rate of rising (dp/dt max ), were monitored using a non-invasive blood pressure analyzer and color Doppler echocardiography. The antioxidative activity in the myocardial tissue was measured. The myocardial enzymatic activity was further estimated by determining the serum levels of creatine kinase (CK), lactate dehydrogenase (LDH), cardiac troponin T (cTnT), and glucagon-like peptide-1 (GLP-1), as well as the expression of GLP-1R in the myocardial tissue. Results: Exenatide preconditioning attenuated the oxidative stress injury and promoted the myocardial function in I/R-induced myocardial injury, while the application of block copolymer PLL-PEG-PLL as a potential exenatide nanocarrier with sustained release significantly enhanced the bioavailability of Dr.
Introduction
Myocardial ischemia-reperfusion (I/R) injury (MI/RI) as a common pathophysiological entity of cardiovascular diseases is one of the leading causes of death worldwide [1, 2] . Lipid peroxidation, reactive oxygen species (ROS) production, apoptosis, and DNA/RNA injury are reported to be associated with MI/RI [3] . If these factors are not purged, they may ultimately induce a high incidence of chronic heart failure [4] [5] [6] . Hence an increasing number of cardiologists are interested in the strategies to reduce MI/RI, including medical treatment, surgical intervention, and gene therapy [7] [8] [9] . Glucagon-like peptide-1 (GLP-1) is an incretin hormone modulating glucose homeostasis [10, 11] . Recent research has demonstrated that GLP-1 can also play an important role in cardiovascular physiology [12] . Previous studies showed that GLP-1 may protect the brain and gastrointestinal tract against I/R through several signaling pathways [13, 14] .
Exenatide as the agonist of GLP-1 is reported to have anti-inflammatory and antioxidant stress effects by regulating blood glucose, blood lipids and blood pressure, and a cardiovascular protective effect by ameliorating myocardial infarction and heart failure [15] [16] [17] . Recent studies have shown that exenatide may attenuate MI/RI via modulating cardiomyocyte metabolism [18] [19] [20] . In addition, exenatide could exert a cardioprotective effect by improving the mitochondrial function in an in-vitro model of hypoxia/reoxygenation (H/R) [21] . Pretreatment with exenatide may decrease abnormalities of myocardial cell mitochondrial and reduce oxidative stress, and enhance ATP synthesis and mitochondrial ATPase activity in myocardial cells subjected to H/R [21] . However, the half-life of exenatide in circulating blood is short as 9.5 hours, which limits its clinical application because of the need for frequent injections [22] .
It is therefore an urgent task to innovate more effective strategies for enhancing the drug sensitivity and myocardial function in the treatment of MI/RI. To overcome the limitation of exenatide in therapeutic application, we developed a poly(L-lysine)-poly(ethylene glycol)-poly(L-lysine) (PLL-PEG-PLL) polyplex as an exenatide nanocarrier, which is composed of a linear PEG block polymer and two brush-like PLL block polymers by combining the positively charged PLL brush block polymer with the negatively charged exenatide through electrostatic interactions at pH 7.4 for the sake of enhancing the circulation life of exenatide in vivo, and prolonging the pharmacological effect of exenatide/PLL-PEG-PLL nanoparticles in protecting the heart against I/R-induced myocardial injury.
Materials and Methods

Synthesis of PLL-PEG-PLL
PLL-PEG-PLL was synthesized by using the previously described method [23] [24] [25] [26] . Briefly, poly(ε-benzyoxycarbonyl-L-lysine)-poly(ethylene glycol)-poly(ε-benzyoxycarbonyl-L-lysine) (PZLL-PEG-PZLL) was firstly synthesized by dissolving and stirring H 2 N-PEG-NH 2 (Sigma-Aldrich, USA) with N, N-dimethylformamide (DMF) at pH 7.4 at 37 o C for 6 h. The benzyl groups of PZLL were then deprotected in the presence of bromine hydride (HBr), trifluoroacetic acid (CF 3 COOH), and acetic acid (CH 3 COOH) to obtain the final product PLL-PEG-PLL, as depicted in Fig. 1 .
Cytotoxicity assay of PLL-PEG-PLL
A 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) colorimetric assay [27] [28] [29] [30] [31] [32] was performed to assess the cytotoxic effects of PLL-PEG-PLL. Briefly, the heart from 2-day-old newborn rats was removed, rinsed by D-Hanks solution (Solarbio, Beijing), and then cut into pieces of 1 mm 3 in the primary myocardial cell essential medium (PMEM) (PriCells, Wuhan) supplemented with 0.25% trypsin. It was then incubated at 37°C for 10 min, and subsequently centrifuged at 1,000 rpm for 10 min to harvest the cells. After 2-h culturing, fibroblasts adhering to the wall were gently blown to the medium. All the medium supernatants were centrifuged at 3,000 rpm for 5 min, and the supernatant was discarded. The contractile cardiomyocytes were obtained by adding PMEM containing 10% calf serum and bromodeoxyuridine (BrdU, 10 mM). The obtained cardiomyocytes were identified with anti-myoglobin antibody and anti-α-striated muscle sarcomere actin (α-SCA) antibody by immunohistochemical method. The acquired cardiomyocytes were seeded at a density of 5×10 5 /L cells per well in a 96-well poly-D-lysine-coated plate and maintained in PMEM supplemented with 10 % fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37 o C in a humidified incubator with 5 % CO 2 . The cells were treated with a concentration gradient of PLL-PEG-PLL diluted with normal saline (0.9%), and then cultured at 37°C for 24 h. To determine the cell viability, the wells were added with MTT (20 μL), and then treated with ethanol-dimethyl sulfoxide (DMSO) (1:1, 100 μL) to solubilize the dark blue crystals of MTT forma zan completely (~20 min). The absorbance or optical density (OD) of per well at 570 nm was measured on a microplate multimode reader (Turner Biosystems, USA). The blank control was taken from wells without cells, which were also cultured with the MTT. Cells incubated in the wells without polymers were used as a negative control. PLL-PEG-PLL was used as a potential cytotoxicity sample. The percentage of relative cell viability was calculated by comparing the value of treated cells with that of untreated cells using the following equation: (OD sample -OD blank )/(OD cells -OD blank )×100% [29] .
Encapsulation and in vitro release of exenatide in PLL-PEG-PLL
To assess the encapsulation of exenatide by PLL-PEG-PLL, a certain amount of exenatide (5 mg/mL) in phosphate buffered solution (PBS) (0.01 mM, pH 7.4) was mixed with PLL-PEG-PLL in PBS, in which the mixed solution was dialyzed in a dialysis tubing (MWCO, 100 kDa). The dialysis of free exenatide in PBS was performed under the same conditions to serve as controls. When the free exenatide in the control experiment was completely dialyzed, the quantification of exenatide in the outer dialysate of the polymer solution was measured using the enzyme-linked immunosorbent assay (ELISA) (Roche, Germany) according to the manufacturer's instructions. The exenatide/PLL-PEG-PLL copolymers were characterized with a nanoparticle size analyzer and transmission electron microscope (TEM). Exenatide release from exenatide/ PLL-PEG-PLL was measured using a dialysis method (MWCO, 100 kDa) at 37 o C with 5 mL of exenatide/PLL-PEG-PLL against a PBS (0.1 M, pH 7.4) at the set time intervals. Finally, the released exenatide was quantified by ELISA according to the manufacturer's instruction. exenatide and exenatide/PLL-PEG-PLL in rat blood was detected using a double-antibody sandwich ELISA kit. Blood glucose levels were measured using the glucose oxidase-peroxidase (GOD-POD) methods [33] .
Evaluation of the exenatide concentration in circulating blood and blood glucose test
Animals and the surgical process of MI/RI
Male Sprague-Dawley rats weighing 170-190 g were obtained from the Laboratory Animal Unit of Jiaxing University (Jiaxing, China). All experimental procedures were approved by the Ethics Committee for Animal Care and Use at Jiaxing University. A total of 50 rats were generally anesthetized by intraperitoneal (i.p.) injection with 1% pentobarbital sodium (50 mg/kg bw), and then equally randomized into five groups:
1) sham-operated group (Sham group), where rats were only treated with separation of the left anterior descending coronary artery at 2 mm on the lower margin of the left atrial appendage; 2) I/R group, where I/R was induced by clamping the left anterior descending coronary artery located at a 2-mm distance from the lower margin of the left atrial appendage for 0.5 h, followed by 2 h reperfusion; 3) exenatide + I/R group (Exenatide group), where the rats were pretreated subcutaneously with exenatide (5 μg/kg bw) in the abdomen at 30 min prior to the I/R procedure, and subsequently dosed daily for 6 days; 4) PLL-PEG-PLL + I/R group (P group), where PLL-PEG-PLL (94.8 μg/kg bw) was administrated at 30 min prior to the I/R procedure, and subsequently dosed daily for 6 days; and 5) exenatide/PLL-PEG-PLL + I/R group (Exenatide/P group), where exenatide/P (99.8 μg/kg bw [containing 5 μg/kg bw exenatide]) was administrated at 30 min prior to the I/R procedure, and subsequently dosed on 3-day intervals.
General monitoring of the rat physiological index
The coronary blood flow (CBF) was measured with a color Doppler echocardiograph (GE, USA). A greater than 90% reduction in CBF of the left anterior descending coronary artery was confirmed during the vessel occlusion before reperfusion [29] . The parameters of the left ventricular ejection fraction (LVEF), the left ventricular end-diastolic pressure (LVEDP), and the left ventricular pressure maximal rate of rising (+dp/dt max ) were monitored with a pressure probe connecting the cardiac catheter in the left ventricle being from the right common carotid artery by the color Doppler echocardiograph. The heart rate (HR) and blood pressure (BP) were monitored through the caudal artery using a Non-invasive Blood Pressure Analyzer (Visitech, USA).
ELISA assay
Blood was collected at 120 min after reperfusion, and centrifuged at 12,000 × g at 4°C for 10 min to harvest the serum. The resected rat myocardial tissue was homogenized in protein lysate buffer in icecold normal saline and then centrifuged to harvest the supernatant. The serum levels of creatine kinase (CK), lactate dehydrogenase (LDH), cardiac troponin T (cTnT) and glucagon-like peptide-1 (GLP-1), as well as the levels of superoxide dismutase (SOD) and malondialdehyde (MDA) in the myocardial tissue, were measured with the double-antibody sandwich ELISA kits (Abcam, Shanghai) according to the manufacturer's instructions.
Histopathological assessment in the myocardial tissue
The heart tissue was fixed in 4% neutral PBS/paraformaldehyde, paraffin-embedded, sliced into 4-µm sections, and stained with hematoxylin & eosin (HE) staining. The histopathological changes were examined under an optical microscope (Leica, Germany) and graded according to the degree of damage based on the percentage of involvement of the myocardium [2, 34] . The damage quantification from 10 areas corresponding to the myocardial tissue was graded using the following parameters: cellular edema, cell apoptosis, necrocytosis, hemorrhage, and myocardial fiber twisting and fracture based on a four-score system (0, histopathological changes ≤10%; 1, = 11-25%; 2, =26-50%; 3, =51-75%; and 4, =76-100%). The mean score for each parameter was calculated and subjected to statistical analysis.
Immunohistochemistry
The 4-μm myocardial tissue paraffin sections were deparaffinized, rehydrated, and treated with 3% hydrogen peroxide (H 2 O 2 ) to remove endogenous peroxidase. Then they were incubated with the primary anti-GLP-1 receptor (anti-GLP-1R) antibody (Abcam, Shanghai) overnight at 4°C. The secondary antibody was horseradish peroxidase-labeled streptavidin. Microphotographs were taken with Leica DM2000LED imaging system.
Western blotting analysis
Western blotting analysis was performed following previous reports [35] [36] [37] . Briefly, the rat myocardial tissue was homogenized in protein lysate buffer. An equal amount of homogenate protein was subjected to 10% sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and then electrophoretically transferred to the nitrocellulose membrane. After blocking with 5% skim milk in Tris-buffered saline (TBS)-Tween 20 (TBST) for 1 h, the membrane was immunoblotted with primary anti-GLP-1R antibody at 4°C overnight and treated with alkaline phosphatase-conjugated secondary antibody. Blots were stained via β-actin antibody.
The products were visualized and analyzed using enhanced chemiluminescence and FluorChem system (Thermo, USA).
Statistical analysis
Data are expressed as the mean ± standard deviation (Mean ± SD). Microsoft Excel 2016 database and GraphPad Prism 5 software were used to record and analyze all the data. Statistical differences were determined using Student's t-test or one-way analysis of variance (ANOVA) with posthoc test. A value of less than 0.05 (p<0.05) in a two-tailed test was considered statistically significant.
Results
Synthesis and characterization of PLL-PEG-PLL
The PLL-PEG-PLL nanoparticles were composed of a linear PEG block and two brushlike PLL blocks. The synthesis route and structure of PLL-PEG-PLL are demonstrated in Fig.  1 . The molecular weight of PLL-PEG-PLL was 15.5 kDa (obtained from 1 H NMR) (Fig. 2A) . The images of PLL-PEG-PLL and exenatide/PLL-PEG-PLL polymer were observed by TEM. They displayed an orbicular structure with a diameter of 31 nm and 77 nm respectively (Fig.  2B , Table. 1). 
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Encapsulation of exenatide in and release of exenatide from PLL-PEG-PLL
Exenatide was efficiently loaded by the copolymer PLL-PEG-PLL at physiological pH through hydrophobic interaction between the negatively charged exenatide (the isoelectric point of exenatide is ~4.86) and the positively charged PLL (Fig. 2C) . The loading capacity of exenatide in PLL-PEG-PLL was determined to be ~5.01% (Table 1 ). The in vitro exenatide release from PLL-PEG-PLL was detected using dialysis. Under 0.1 M PBS (close to physiological ionic strength), sustained release of exenatide was observed, with 8.34 % of exenatide released over a period of 2 h, 60.31% over a period of 1 day, and 88.74% over a period of 3 days (Fig.  2D) .
Cell viability
The cytotoxicity of PLL-PEG-PLL on cardiomyocytes was monitored within 24-h culturing. PLL-PEG-PLL was atoxic at the concentrations of ≤50 μg/mL and exhibited low cytotoxicity and high relative cell viability (minimum mean was ~89.2%), even when administered at a maximum dose of 200 μg/mL (Fig. 2E) .
The exenatide concentration in circulating blood and blood glucose level
After a single injection of 5 μg/kg bw exenatide, the exenatide level in circulating blood of the rats rapidly peaked to the maximum concentration (C max ) of 678.85 ng/mL) at 2 h (time of maximum concentration, T max ) and reduced to baseline level within 24 h (Fig. 2F) . It reached the C max 51.19 ng/mL at a T max 6 h and declined to the baseline value within 3 days in exenatide/PLL-PEG-PLL rats. These data indicate that the release of exenatide in exenatide/PLL-PEG-PLL rats was substantially sustained compared with that in exenatide rats. The average blood glucose levels over time were measured in rats administered with free exenatide and exenatide-loaded polymers and compared with the normal control rats. It was found that blood glucose levels in rats injected with the free exenatide decreased within the normal range for approximately 4 h, and then slowly went up. In contrast, administration of the exenatide/polymer complex reduced blood glucose levels to 3.85 mmol/L after 1 h (Fig. 3) .
Physiological parameters alterations
Myocardial I/R insult reduced LVEF, +dp/dt max and BP, and increased LVEDP and HR. Compared with I/R group, administration of exenatide increased the LVEF, +dp/dt max , and BP levels, and reduced the LVEDP and HR values (p<0.05). In addition, pretreatment with exenatide/PLL-PEG-PLL significantly ameliorated the mentioned above, compared with pretreatment with free exenatide (p<0.05) (Fig. 3) .
Serum levels of CK, LDH, cTnT, and GLP-1 in rats of different groups
After MI/RI, serum CK, LDH, and cTnT levels were increased, and GLP-1 level was decreased. After pretreatment with exenatide, CK, LDH, and cTnT levels were decreased, and GLP-1 level was increased compared with those in I/R group (p<0.05). Similarly, exenatide/ PLL-PEG-PLL polyplexes were more effective compared with free exenatide (p<0.05) (Figs. 4A-D).
SOD activity and MDA level in the myocardial tissue
Myocardial I/R reduced SOD activity and increased MDA level in the myocardial tissue. Compared with I/R group, preconditioning with exenatide augmented the activity of SOD whereas decreased the level of MDA (p<0.05). Compared with free exenatide-preconditioning, exenatide/PLL-PEG-PLL-pretreatment markedly improved SOD activity and decreased MDA level (p<0.05) (Figs. 4E-F) .
Histopathological changes of the myocardial tissue
Light microscopy showed several hemorrhagic lesions and myocardial edemas in intermuscular spaces after the I/R surgery. There were obvious cardiomyocyte edema (myocardial cytoplasmic vacuole formation), apoptosis, necrosis, dissolution, intermuscular hemorrhage, and wave-twisted deformation of cardiac muscle fibers in I/R group. These histopathological alterations were markedly attenuated in exenatide/PLL-PEG-PLLpretreatment group and moderately alleviated in exenatide-preconditioning group (p<0.05) (Fig. 5) . 
Discussion
In this study, we developed an exenatide nanocarrier PLL-PEG-PLL to prolong the in vivo half-life of exenatide, demonstrating that pretreatment with exenatide or exenatide/ PLL-PEG-PLL NPs was able to alleviate MI/RI. The block copolymer is composed of two brush-like PLL block polymers and a linear PEG block polymer, wherein the negatively charged exenatide combines with the positively charged PLL brush block polymers through electrostatic interactions at physiological pH (pH 7.4). The loaded exenatide can be released in a sustained manner, thus significantly improving the bioavailability of free exenatide. Exenatide is known as a synthetic version of exendin-4 with a 39-amino-acid peptide as an insulin secretagogue to exert the glucoregulatory effects [38] . It is often used for patients whose diabetes is not well-controlled by other oral medications which are injected subcutaneously twice per day [39] . Exenatide can also be used to protect the myocardial function [40, 41] . However, the overall role of exenatide in MI/RI is unclear, and there are few studies focusing on the application of an exenatide-loaded nanocarrier for the treatment of MI/RI. In the present study, we delineated an important myocardial preservative role of exenatide in MI/RI through exenatide-loaded nanocarrier PLL-PEG-PLL preconditioning.
I/R injury is a tissue damage occurring when blood supply returns to the tissue after a period of ischemia, wherein the absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in oxidative injury and inflammation through the induction of oxidative stress along with restoration of the normal function [42, 43] . Although the functional consequences of depriving a tissue of its blood supply have been appreciated for many years, the cardiovascular diseases initiated by local or systemic tissue ischemia remain the leading cause of death worldwide. Oxidative stress, reflecting an imbalance between the ability of the biological system and the systemic manifestation of reactive oxygen species to repair the resulting damage, can trigger cell apoptosis and even necrosis. SOD is an important antioxidant defense protein in nearly all living cells exposed to oxygen, whereby it can catalyze the dismutation of the superoxide radical into hydrogen peroxide or either ordinary molecular oxygen [44, 45] . The results described in this study demonstrate that the increased level of myocardial I/R-induced oxidative stress was significantly inhibited by the upregulation of SOD and downregulation of MDA after pretreatment with exenatide or exenatide/PLL-PEG-PLL NPs. Meanwhile, preconditioning with exenatide or exenatide/PLL-PEG-PLL polyplexes recovered the abnormity of cardiac functional parameters (LVEF, LVEDP, +dp/dt max , BP, and HR) and myocardial enzymes (CK, LDH, and cTnT) to a certain extent. Therefore, exenatide/PLL-PEG-PLL may potentially be useful for the treatment of I/R-induced myocardial injury by modulating the status of oxidative stress. Exenatide is associated with a modest increase in BP and a slight reduction in HR after cardiac I/R; yet the relevant mechanism remains unclear at present [46] , and further investigations to explore underlying mechanism are warranted.
GLP-1 is a thirty-amino acid long peptide incretin hormone deriving from the tissuespecific posttranslational processing of the proglucagon gene. It was originally found to increase insulin synthesis and secretion. A recent study showed that GLP-1 played a cardioprotective role through an antioxidant mechanism by decreasing fatty acid oxidation and increasing glucose oxidation [47, 48] . In addition, its receptor was found to be extensively expressed in the vascular tree in normotensive rats [49] . It was found in the present study that pretreatment with exenatide and exenatide/PLL-PEG-PLL could raise the levels of BP, LVEF, and +dp/dt max , and reduce LVEDP and HR through improving GLP-1 and its receptor expression, suggesting that the antioxidative and blood flow-regulatory effects of GLP-1R are important mechanisms underlying myocardial preservation effect of exenatide in MI/RI.
